

# Malmö Preventive Project

<https://neurodegenerationresearch.eu/survey/malmo-preventive-project/>

## **Title of cohort**

Malmö Preventive Project

## **Acronym for cohort**

MPP

## **Name of Principal Investigator - Title**

Prof

## **Name of Principal Investigator - First name**

Olle

## **Name of Principal Investigator - Last name**

Melander

## **Address of institution -Institution**

Dept of Clinical Sciences, Malmö

## **Address of institution - Street address**

Jan Waldenströms gata 35

## **Address of institution - City**

Malmö

## **Address of institution - Postcode**

20502

## **Country**

Sweden

## **Website**

[http://www.med.lu.se/klinvetmalmo/befolkningsstudier/malmoe\\_kost\\_cancer\\_och\\_malmoe\\_foeret](http://www.med.lu.se/klinvetmalmo/befolkningsstudier/malmoe_kost_cancer_och_malmoe_foeret)

## **Contact email**

**Funding source**

**Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?**

Alzheimer's disease and other dementias

**Q1b. When are studies on the above condition(s) expected to become possible?**

2016-2020

**Q2a. In a single sentence what is the stated aim of the cohort?**

MPP started as a primary prevention project at the Medical Clinic in Malmö, with focus on improvement of health of industrial workers

**Q2b. What distinguishes this cohort from other population cohorts?**

It is one of the largest prospective cohorts in Sweden

**Q3a. i) Number of publications that involve use of your cohort to date**

>1000

**Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)**

**Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available**

Nilsson ED, Melander O, Elmståhl S, Lethagen E, Minthon L, Pihlgård M, Nägga K. Copeptin, a Marker of Vasopressin, Predicts Vascular Dementia but not Alzheimer's Disease. J Alzheimers Dis. 2016 Apr 12;52(3):1047-53

**Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population**

**Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:**

26

**Q4a. Study criteria: what is the age range of participants at recruitment? To:**

61

**Q4b. Study criteria: what are the inclusion criteria?**

Residents in Malmö, born 1921-1949, initially only men were invited but later on also women

**Q4c. Study criteria: what are the exclusion criteria?**

**Q5. What is the size of the cohort (i.e. how many participants have enrolled)?**

More than 15,000 participants

**Q6a. Please describe what measures are used to characterise participants**

Data are obtained from questionnaires, analyses of blood samples, national and local registers

**Q6b. Are there additional measures for participants with a clinical disorder?**

Yes, but only in conjunction with the screening

**Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?**

Yes

**If yes please specify**

Primarily cancer, cardiovascular diseases and diabetes, Dementia

**Q7. What is the study design (select all that apply)?**

Prospective cohort|Longitudinal

**Q8. Are your cases matched by**

Other health assessment

**Q9a. Does your study include a specialised subset of control participants?**

No

**Q9b. If your study includes a specialised subset of control participants please describe**

**Q10a. i) Please enter the data collection start date**

Screening started in 1974, but data before that date are obtained from national and local registries

**Q10a. ii) Please enter the data collection end date**

Currently we have follow-up data until Dec 31, 2014

**Q10a. iii) Is data collection for this study**

Data analysis ongoing|Closed to new patients

**Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?**

**Q11. Is data collected**

Through links to other records or registers (e.g dental records, police records etc)

**Other please specify here**

National medical and population registers (SoS, SCB), Tax authority etc

**Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?**

No

**Q13a. Please give information on the format and availability of data stored in a database (1)**

% available

**Q13a. Please give information on the format and availability of data stored in a database (2)**

% available

**Q13a. Please give information on the format and availability of data stored in a database (3)**

% available

**Q13a. Please give information on the format and availability of data stored in a database (4)**

% available

**Other (please specify)**

% available

**Q13b. Please give information on the format and availability of data held as individual records (1)**

Data is held as individual records

% available

100

**Q13b. Please give information on the format and availability of data held as individual records (2)**

No

% available

**Q13b. Please give information on the format and availability of data held as individual records (3)**

Data held on computer based records

% available

100

**Q13b. Please give information on the format and availability of data held as individual records (4)**

**% available**

**Please specify language used**

English, Swedish

**Q14a. Is data available to other groups?**

Yes

**Q14b. If data is available to other groups what is the access policy/mechanisms for access?**

Apply to PI or co-ordinator at resource|Access committee mechanism|Local/ regional access|National access|International access|Access to industry|Access for pilot studies permitted|Applicant needs to provide separate external ethics approval|Resource has own ethics approval so usually no need for separate external ethics approval

**Q15. What data sharing policy is specified as a condition of use?**

Data made publicly available after a specified time point

**Q16a. Are tissues/samples/DNA available to other groups?**

Yes

**Q16b i) If yes, please describe below:**

Living donors: blood derivatives|Living donors: DNA

**Q16b. ii) In what form are tissues/samples/DNA supplied?**

Secondary samples:(derivatives of primary samples)|Secondary samples: plasma|Secondary samples: DNA

**Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?**

Yes

**Q17. Is information on biological characteristics available to other groups?**

Yes, for all the cohort

**Number of Patients**

**% of total cohort**

**Types:**

Population Cohorts

**Member States:**

Sweden

**Diseases:**

Alzheimer's disease & other dementias

**Years:**

2016

**Database Categories:**

N/A

**Database Tags:**

N/A